- ?? Blog ActionCovid1984.org
- ?? Irish Examiner
- Inverse
- ?? Gript media
- Blake-Lemoine - LaMBDA
- ?? Over Dee Wall
- The Defender News
- ?? BreakingNews.ie
- Dr Vernon Coleman
- Rebel News
- Vaccine Choice Canada NEWS
- SHFT Plan
- The Expose
- ?? Robert Pierzyński PJ
- James Roguskii - Substack
- ?? The Burkean
- Liberty Tactics IM
- stewpeters.com
- Technocracy News
- Interesting Engineering
- ?? Media Hub Ireland
- ?? The Irish Inquiry
- ?? Andy Heasman
- ?? GriptMedia
- ?? WeThePeople.ie
- ?? Action-Covid-1984
- ?? Lets wake up our Capital
- ?? Lets Wake Up Call!!!
- WW Freedom Rallies
- Piers Corbyn
- ?? Tracey OMahony
- ?? The Irish Git
- eIRe is falling
- Peter Madden Channel
- rish Farmers,Food & Family
- Gemma O'Doherty
What's new
What's new
Agenda of the CVMP meeting 8-10 September 2026
Agenda of the CVMP meeting 8-10 September 2026
8 September 2026
Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Date of authorisation: 13/02/2017, Revision: 27, Status: Authorised
Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Date of authorisation: 13/02/2017, Revision: 27, Status: Authorised
8 September 2026
Member states contact points for translations review
Member states contact points for translations review
8 September 2026
Human medicines European public assessment report (EPAR): Gardasil 9, human papillomavirus 9-valent vaccine (recombinant, adsorbed), Date of authorisation: 10/06/2015, Revision: 30, Status: Authorised
Human medicines European public assessment report (EPAR): Gardasil 9, human papillomavirus 9-valent vaccine (recombinant, adsorbed), Date of authorisation: 10/06/2015, Revision: 30, Status: Authorised
8 September 2026
EMA/FVE information session for veterinary students: the importance of pharmacovigilance, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 October 2026, 16:00 (CEST) to 13 October 2026, 17:15 (CEST)
EMA/FVE information session for veterinary students: the importance of pharmacovigilance, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 October 2026, 16:00 (CEST) to 13 October 2026, 17:15 (CEST)
7 September 2026
Human medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Date of authorisation: 27/04/2026, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Date of authorisation: 27/04/2026, Revision: 3, Status: Authorised
7 September 2026
Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products
Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products
7 September 2026
Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 5, Status: Authorised
7 September 2026